PRQR - ProQR Therapeutics N.V.
| Previous Close | 7.050 |
| Open | 7.050 |
| Bid | 7.000 x 1800 |
| Ask | 9.050 x 1100 |
| Day's Range | 6.851 - 7.050 |
| 52 Week Range | 2.750 - 7.450 |
| Volume | 12,331 |
| Avg. Volume | 90,966 |
| Market Cap | 223.453M |
| Beta | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.857 |
| Earnings Date | May 15, 2018 - May 21, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.83 |
- GlobeNewswire•4 days ago
ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
A presentation will be delivered by Dr. Erwin van Wijk from Radboudumc at Nijmegen, the Netherlands on QR-421a for Usher Syndrome during the USH2018 International Symposium to be held on July 19 – 21, 2018 in Mainz, Germany.
- GlobeNewswire•18 days ago
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.. QR-313 is a first-in-class ...
- GlobeNewswire•last month
ProQR to Present at the JMP Life Sciences Conference
LEIDEN, the Netherlands, June 14, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
- GlobeNewswire•last month
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced a collaboration with nonprofit organizations EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) to develop QR-313 for patients with dystrophic epidermolysis bullosa (DEB) caused by mutations in exon 73 of the COL7A1 gene. Under the agreement, EBRP and EBMRF will provide up to approximately $5 million in matching funding to ProQR under a venture philanthropy model, to co-fund the clinical development of QR-313.
- ACCESSWIRE•last month
Wired News – Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinson’s Treatment
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences.
- GlobeNewswire•last month
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
LEIDEN, The Netherlands, June 04, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
- GlobeNewswire•2 months ago
ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr. Yi-Tao Yu to the company's scientific advisory board. "Dr. Yu is a pioneer of targeted RNA editing to correct protein translation defects caused by premature termination codons,” said Daniel de Boer, chief executive officer of ProQR.
- Associated Press•2 months ago
ProQR: 1Q Earnings Snapshot
The Leiden, Netherlands-based company said it had a loss of 41 cents per share. The company's shares closed at $4.50. A year ago, they were trading at $5.20. _____ This story was generated by Automated ...
- GlobeNewswire•2 months ago
ProQR Announces Results for the First Quarter of 2018
Eight out of twelve patients have been enrolled in a Phase 1/ 2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected ...
- GlobeNewswire•3 months ago
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
LEIDEN, the Netherlands, April 30, 2018-- ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, ...
Market Realist•3 months agoHow Vertex Pharmaceuticals’ Drugs Performed in 1Q18
In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million. It fell 3% QoQ (quarter-over-quarter).
- GlobeNewswire•3 months ago
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled. ProQR to present two abstracts on programs for Fuchs endothelial corneal dystrophy and Stargardt’s disease at the ARVO annual meeting. The company will also deliver a presentation during the Foundation Fighting Blindness/Casey Innovation summit prior to ARVO.
- Zacks•3 months ago
Will ProQR Therapeutics (PRQR) Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in ProQR Therapeutics N.V. (PRQR)
- Associated Press•5 months ago
ProQR reports 4Q loss
The Leiden, Netherlands-based company said it had a loss of 46 cents per share. For the year, the company reported that its loss widened to $49.3 million, or $1.94 per share. The company's shares closed ...
- Simply Wall St.•5 months ago
Where ProQR Therapeutics NV. (NASDAQ:PRQR) Stands In Terms Of Earnings Growth Against Its Industry
After looking at ProQR Therapeutics NV.’s (NASDAQ:PRQR) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...
- Market Realist•5 months ago
How Did Kalydeco Perform in 4Q17 and 2017?
How Is Vertex Pharmaceuticals Positioned after 4Q17?
